碘伏对恶性胸腔积液的硬化治疗效果观察  

Efficacy and safety of iodopovidone as sclerosing agent in patients with malignant pleural effusion

作　　者：王兴元[1] 范利娟[1] 杨善进[1] 周红霞[1] 曹红兵[1] 

机构地区：[1]解放军第359医院,江苏镇江212001

出　　处：《临床肺科杂志》2011年第4期566-567,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的恶性胸腔积液是癌症晚期的一种表现,硬化治疗是此阶段最好的处理方式,本研究评价使用碘伏作为硬化剂对胸腔积液患者的疗效和安全性。方法分析10年间共52例恶性胸腔积液患者在胸腔注入碘伏硬化治疗后的临床资料,总结碘伏对恶性胸腔积液患者的疗效和安全性。结果 52例患者共完成112次硬化治疗,无一例因置管相关的死亡发生,最常见的副作用是41例(78.8%)患者发生轻度即刻胸膜疼痛。总的成功率达100%。结论本研究提示,碘伏对恶性胸腔积液的治疗安全有效,只有轻微的副作用,可能是目前较为理想的胸腔积液硬化剂。Objective Malignant pleural effusions are a common clinical problem in patients with neoplastic disease,Pleurodesis is one of the best methods of controlling malignant pleural effusions（MPE）.The aim of this study was to evaluate the efficacy and safety of iodopovidone pleurodesis in MPE.MethodsA retrospective analysis was performed on patients with MPE who underwent pleurodesis at our hospital between 1999 and 2010.All patients underwent instillation of 20 ml of 10% iodopovidone,80 ml of normal saline and 2 mg/kg of lidocaine through a chest tube,which was clamped for 2 h.The tube was removed when the daily output of fluid was 200 ml.Data on the requirement for additional pleural procedures,adverse events and survival were collected.Results112 pleurodesis procedures were performed in 52 patients.No procedure-related mortality was observed.The most frequent complication was mild thoracic pain that occurred in 41（78.8%） immediately after procedures.A success rate of 100% was observed.None of the patients had recurrences of pleural fluid or required additional pleural procedures during the follow-up period（30 days）.ConclusionsIodopovidone pleurodesis was successful and was associated with only a few minor complications.It appears to be an ideal option for the management of recurrent MPE.

关 键 词：恶性胸腔积液 碘伏 硬化治疗 

分 类 号：R730.5[医药卫生—肿瘤]